Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133)

The LIFE study was conducted from 1995-2001. This study was conducted in 9193 patients with high blood pressure and thickening of the main pumping chamber of the heart. The results showed that after an average treatment time of 4.8 years, treatment that was based on losartan was better than treatment based on atenolol for reducing the risk of having a stroke. The main study results were published in Dahlof et al. Lancet 2002;359:995-1003.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart) Cardiomegaly Cardiovascular Diseases Heart Diseases Hypertension Hypertrophy Hypertrophy, Left Ventricular Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Vascular Diseases

Age range

55 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age 55 to 80 years
Males and females
Hypertension (160-200/95-115 mm Hg
ECG evidence of left ventricular hypertrophy

Exclusion criteria

Need for treatment with angiotensin converting enzyme inhibitors, or open- label angiotensin receptor blockers or beta-blockers
Myocardial infarction or stroke within 6 months

Treatment and study plan

MK0954, /Duration of Treatment : 5 Years

Drug

Comparator : atenolol /Duration of Treatment : 5 Years

Drug

Primary outcomes

Composite of cardiovascular death, fatal and nonfatal stroke, fatal and nonfatal myocardial infarction (heart attack)

Secondary outcomes

cardiovascular death, stroke, myocardial infarction, all-cause mortality, hospitalization for heart failure, new-onset diabetes mellitus

Sponsors and collaborators

Lead sponsor

Organon and Co

Industry

Registry information

Official study title

A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy

Important dates

Study start: 1995
Primary completion: 2001
Study completion: 2001
First posted: Jun 20, 2006
Registry last updated: Feb 15, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed